Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 1. Reported cases of notifiable diseases and rates per 100,000, excluding U.S. territories - - United States, 2017
Disease Case Count Rate
Anthrax — —
Arboviral diseases
Chikungunya virus disease 156 0.05
Eastern equine encephalitis virus disease
Neuroinvasive 5 0.00
Non-neuroinvasive — —
Jamestown Canyon virus disease
Neuroinvasive 58 0.02
Non-neuroinvasive 17 0.01
La Crosse virus disease
Neuroinvasive 63 0.02
Non-neuroinvasive — —
Powassan virus disease
Neuroinvasive 33 0.01
Non-neuroinvasive 1 0.00
St. Louis encephalitis virus disease
Neuroinvasive 6 0.00
Non-neuroinvasive 5 0.00
West Nile virus disease
Neuroinvasive 1,425 0.44
Non-neuroinvasive 672 0.21
Western equine encephalitis virus disease
Neuroinvasive — —
Non-neuroinvasive — —
Babesiosis
Total 2,368 0.94
Confirmed 1,994 0.79
Probable 374 0.15
Botulism
Total 177 0.05
Foodborne 19 0.01
Infant * 137 3.48
Other (wound & unspecified) 21 0.01
Brucellosis 140 0.04
Campylobacteriosis 67,537 20.73
Chancroid 7 0.00
Chlamydia trachomatis infection 1,708,569 524.55
Cholera 10 0.00
Coccidioidomycosis † 14,364 10.93
Cryptosporidiosis
Total 11,414 3.50
Confirmed 8,043 2.47
Probable 3,371 1.03
Cyclosporiasis 1,194 0.40
Dengue virus infections §
Dengue 437 0.13
Dengue-like illness 8 0.00
Severe dengue 9 0.00
Diphtheria — —
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 5,762 1.83
Ehrlichia chaffeensis infection 1,642 0.52
Ehrlichia ewingii infection 45 0.01
Undetermined ehrlichiosis/anaplasmosis 269 0.09
Giardiasis 15,193 5.94
Gonorrhea 555,608 170.58
Haemophilus influenzae, invasive disease
All ages, all serotypes 5,548 1.70
Age <5 years 
Serotype b 33 0.17
Non-b serotype 189 0.95
Nontypeable 200 1.00
Unknown serotype 203 1.02
Hansen's disease 94 0.03
Hantavirus infection, non-hantavirus pulmonary syndrome 2 0.00
Hantavirus pulmonary syndrome 33 0.01
Hemolytic uremic syndrome post-diarrheal 338 0.11
Hepatitis **
A, acute 3,365 1.03
B, acute 3,409 1.05
B, perinatal infection †† 31 0.39
C, acute 4,225 1.36
Confirmed 3,213 1.04
Probable 1,012 0.33
Human immunodeficiency virus diagnoses 33,938 10.42
Influenza-associated pediatric mortality §§ 126 0.17
Invasive pneumococcal disease ¶¶
All ages 19,780 8.15
Confirmed 19,620 8.08
Probable 160 0.07
Age <5 years  1,234 0.47
Confirmed 1,220 7.64
Probable 14 0.09
Legionellosis 7,458 2.29
Leptospirosis 72 0.03
Listeriosis 887 0.27
Lyme disease
Total 42,743 13.18
Confirmed 29,513 9.10
Probable 13,230 4.08
Malaria 2,056 0.63
Measles
Total 120 0.04
Indigenous 99 0.03
Imported 21 0.01
Meningococcal disease
All serogroups 353 0.11
Serogroups ACWY 107 0.03
Serogroup B 90 0.03
Other serogroups 25 0.01
Unknown serogroup 131 0.04
Mumps 6,109 1.88
Novel Influenza A virus infections 66 0.02
Pertussis 18,975 5.83
Plague 5 0.00
Poliomyelitis, paralytic — —
Poliovirus infection, nonparalytic — —
Psittacosis 5 0.00
Q fever
Total 193 0.06
Acute 153 0.05
Chronic 40 0.01
Rabies
Animal 4,423 1.36
Human 2 0.00
Rubella 7 0.00
Rubella, congenital syndrome * 5 0.13
Salmonellosis 54,285 16.67
Severe acute respiratory syndrome-associated coronavirus disease — —
Shiga toxin-producing Escherichia coli *** 8,672 2.66
Shigellosis 14,912 4.58
Smallpox — —
Spotted fever rickettsiosis
Total 6,248 1.93
Confirmed 176 0.05
Probable 6,072 1.88
Streptococcal toxic shock syndrome 372 0.18
Syphilis
Total, all stages 101,567 31.18
Congenital * 918 23.30
Primary and secondary 30,644 9.41
Tetanus 33 0.01
Toxic shock syndrome (other than Streptococcal) 30 0.01
Trichinellosis 15 0.00
Tuberculosis 9,105 2.80
Tularemia 239 0.07
Typhoid fever 419 0.13
Vancomycin-intermediate Staphylococcus aureus 109 0.04
Vancomycin-resistant Staphylococcus aureus 3 0.00
Varicella morbidity 8,775 3.30
Varicella mortality 2 0.00
Vibriosis
Total 2,085 0.65
Confirmed 1,497 0.47
Probable 588 0.18
Viral hemorrhagic fevers
Crimean-Congo hemorrhagic fever virus — —
Ebola virus — —
Guanarito virus — —
Junin virus — —
Lassa virus — —
Lujo virus — —
Machupo virus — —
Marburg virus — —
Sabia virus — —
Yellow fever — —
Zika virus
Zika virus disease, congenital *,††† 22 0.56
Zika virus disease, non-congenital 497 0.15
Zika virus infection, congenital *,††† 17 0.43
Zika virus infection, non-congenital 641 0.20
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • * The rate is calculated using population less than 1 year of age.
  • † Reportable in <25 states.
  • § Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).
  • ¶ The rate is calculated using population less than 5 years of age.
  • ** Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm.
  • †† The rate is calculated using population less than 2 years of age.
  • §§ The rate is calculated using population less than 18 years of age.
  • ¶¶ Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
  • *** Includes Escherichia coli O157:H7 and Shiga toxin-positive Escherichia coli (including O157, non-O157, and not serogrouped).
  • ††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/pregnancy/zika/data/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.
Notes:
  • These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
  • The list of nationally notifiable infectious diseases and conditions for 2018 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2017" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2016 by CSTE for national surveillance, that were implemented in January 2017, including updated surveillance case definitions for salmonellosis, shigellosis, vibrioisis, perinatal hepatitis B virus infection, invasive pneumococcal disease, Lyme disease, and tularemia reported through August 7, 2018. Publication criteria for the finalized 2017 data are available at https://wonder.cdc.gov/nndss/documents/2017_NNDSS_Publication_Criteria.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  • Population estimates for incidence rates are July 1st, 2017 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010 - July 1, 2017, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2017), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released June 27, 2018 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2017 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on October 2, 2018 at https://www.census.gov/data-tools/demo/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  • Annual tables for 2016 and later years are available on CDC WONDER.
  • Annual summary reports from 1993-2015 are available as published in the MMWR.
  • NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left).
Suggested Citation: